test

Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer

Conditions

Lung

What is the purpose of this trial?

The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for subjects with Extensive-Stage Small-Cell Lung Cancer (ES SCLC).


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Onyx Pharmaceuticals
Dates:
05/16/2014
Last Updated:
Study HIC#:
1311013003